- The quick rise of GLP-1 weight-loss drugs is set to drive a big shake-up in the stock market.
- The long-term ripple effects of these drugs will impact sectors across equities and economy.
- These are the areas to watch as drugs like Ozempic, Wegovy, and Mounjaro rise in popularity.
With the surging popularity of GLP-1 weight-loss drugs, millions of Americans are poised to collectively shed hundreds of millions of pounds over the next decade — and reshuffle trillions of dollars in the process.
In other words, the stock market is getting Ozempic’ed.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased